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Abstract
Background: Mammalian cells are becoming the prevailing expression system for the production
of recombinant proteins because of their capacity for proper protein folding, assembly, and post-
translational modifications. These systems currently allow high volumetric production of
monoclonal recombinant antibodies in the range of grams per litre. However their use for large-
scale expression of cytokines typically results in much lower volumetric productivity.
Results: We have engineered a HEK293 cell clone for high level production of human recombinant
glycosylated IFND2b and developed a rapid and efficient method for its purification. This clone
steadily produces more than 200 mg (up to 333 mg) of human recombinant IFND2b per liter of
serum-free culture, which can be purified by a single-step cation-exchange chromatography
following media acidification and clarification. This rapid procedure yields 98% pure IFND2b with a
recovery greater than 70%. Purified IFND2b migrates on SDS-PAGE as two species, a major 21 kDa
band and a minor 19 kDa band. N-terminal sequences of both forms are identical and correspond
to the expected mature protein. Purified IFND2b elutes at neutral pH as a single peak with an
apparent molecular weight of 44,000 Da as determined by size-exclusion chromatography. The
presence of intramolecular and absence of intermolecular disulfide bridges is evidenced by the fact
that non-reduced IFND2b has a greater electrophoretic mobility than the reduced form. Treatment
of purified IFND2b with neuraminidase followed by O-glycosidase both increases electrophoretic
mobility, indicating the presence of sialylated O-linked glycan. A detailed analysis of glycosylation
by mass spectroscopy identifies disialylated and monosialylated forms as the major constituents of
purified IFND2b. Electron transfer dissociation (ETD) shows that the glycans are linked to the
expected threonine at position 106. Other minor glycosylated forms and non-sialylated species are
also detected, similar to IFND2b produced naturally by lymphocytes. Further, the HEK293-
produced IFND2b is biologically active as shown with reporter gene and antiviral assays.
Conclusion: These results show that the HEK293 cell line is an efficient and valuable host for the
production of biologically active and glycosylated human IFND2b.
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Background
Interferons (IFNs) are cytokines with major therapeutic
applications based on their antiviral, antiproliferative,
and immunomodulatory activities. Type I IFNs (IFND/E)
are massively produced in most cell types in response to
viral and other microbial infections, and play a vital role
in innate resistance to a wide variety of viruses [1]. The
IFND2 locus comprises three variants, IFND2a, IFND2b
and IFND2c, IFND2b being the predominant one detected
in human genomic DNA [2,3]. Some of the many diseases
treated with IFND2b, alone or in combination, include
type B [4] and C hepatitis [5], several cancers such as
melanoma [6-8], Kaposi's sarcoma [9], chronic myeloid
lymphoma [10,11], and angioblastoma [12]. In the par-
ticular case of hepatitis C, a disease affecting over 170 mil-
lion individuals worldwide, the combination of IFND and
the viral inhibitor ribavirin has become the standard treat-
ment [13-15]. The rising incidence of certain cancers and
viral hepatitis [16,17], in addition to ongoing investiga-
tions of novel therapeutic applications [18] are increasing
the needs for human recombinant IFND2b.
Human recombinant IFND2b used in the clinic is synthe-
sized in bacterial systems. When E. coli are grown in opti-
mal conditions, a few grams (3 to 5) of recombinant
human IFND per litre of culture can be produced [19-21].
Bacterially produced recombinant human IFND2b is mis-
folded and therefore requires refolding into its native con-
formation. Once purified and refolded, the recoveries are
typically lower than 20% [19,20]. This refolding process
also often results in loss of specific activity. In addition,
bacterially produced recombinant human IFND2b lacks
the post-translational O-glycosylation present on the nat-
urally synthesized protein. This non-glycosylated form of
human recombinant IFND2b has a shorter serum half-life
than the glycosylated form [22]. The chemical conjuga-
tion of polyethylene glycol (PEG) molecules to the core
peptide (pegylation) has improved the pharmacodynam-
ics and pharmacokinetics of IFND2b by increasing the
serum half-life [23]. However, the pegylation of IFND2b
has been reported in some cases to reduce its biological
activity [24]. It has also been shown that the size of PEG
molecules and sites of attachment differentially interfere
with the interaction and binding of IFND2b to its receptor
[25]. Nevertheless, the US Food and Drug Administration
approved PEG-IFND2b in 2001 and PEG-IFND2a in 2002
for the treatment of chronic hepatitis C virus infection.
Another common problem associated with the use of
refolded and pegylated IFND (PEG-IFND) is the formation
of neutralizing antibodies. Antibody formation against
PEG-IFND in HCV-infected patients has been associated
with treatment failure [26,27]. In mice, the presence of
contaminating partially unfolded IFN species appears to
play a key role in the appearance of these antibodies [28]
Human and other mammalian cells are expression sys-
tems of choice for the production of secreted recombinant
proteins such as antibodies, sometimes yielding up to
hundreds of milligram to gram quantities of purified
product per liter of culture [29-31]. However, the volu-
metric productivity of human cells for given proteins such
as cytokines (i.e. IFND2b) is often lower by several orders
of magnitude. Originally, IFND for therapeutic use was
purified from the human lymphoblastoid Namalwa cell
line following induction with Sendai virus. Despite the
production of an IFND with high biological activity,
Namalwa cells were abandoned due to a limited produc-
tivity unable to satisfy an ever-growing demand. Other
systems have been tested for the production of IFND2b.
For example, avian eggs have been used for the produc-
tion of human recombinant IFND2b [32,33], although
the glycosylation pattern significantly differs from
IFND2b produced by human peripheral blood leucocytes.
Glycosylated IFND2b can also be produced in insect cells,
but glycosylation is of the potentially immunogenic high-
mannose type and lacks sialylation [34]. These limitations
suggest that mammalian cells are preferable hosts for the
production of fully glycosylated IFND2b. Chinese hamster
ovary (CHO) cells have been used for the production of
various human recombinant interferons. Glycosylated
and biologically active mouse IFND [35] can be produced
in CHO cells. Similarly, Rossman et al have reported the
production of 120 Pg/mL of IFND2b using a glutamine
synthase-amplified vector in the mouse myeloma cell line
NS0 [36]. This is the highest level of glycosylated recom-
binant human IFND2b produced in a mammalian system
reported to date. In vitro, the biological activity of NS0-
produced IFND2b is very similar to that produced by
Namalwa cells.
Here we have successfully engineered a non-amplified
IFN-producing clone derived from the HEK293 mamma-
lian cell line that produces hundreds of milligrams of
IFND2b per liter of serum-free media. The volumetric pro-
duction of IFND2b reproducibly exceeds 200 mg/L in
batch culture and remains stable in the absence of selec-
tion for more than four months in culture. The purified
IFND2b is glycosylated and biologically active. Together
these results demonstrate that cost-effective production
and purification of glycosylated IFND2b from human cells
can be achieved.
Results
Generation of a stable IFND2b-expressing HEK293 cell 
clone and production in fed-batch cultures
The expression plasmid pYD7 encoding the human
IFND2b gene codon-optimized for expression in human
cells (Fig. 1A) is derived from the previously described
pTT vector [37]. The signal peptide sequence, cysteine res-
idues involved in intramolecular cystine formation, and
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Expression plasmid encoding human IFND2b cDNAFigure 1
Expression plasmid encoding human IFND2b cDNA. A) The pYD7-IFND2b expression plasmid has been used to gener-
ate the D9 clone. (Amp) ampicillin, (Blast) blasticidin, (CMV) cytomegalovirus promoter, (enh MLP) adenovirus major late pro-
moter, (IFND2b) human codon-optimized sequence for human IFND2b gene, (pA) polyadenylation sequence, (pMB1ori) 
bacterial origin of replication, (Puro) puromycin, (OriP) Epstein-Barr virus origin of replication, (SV40pA) simian virus 40 poly-
adenylation sequence, (TPL) adenovirus tripartite leader.B) Amino acid sequence of human IFND2b. Signal peptide is under-
lined. The two intramolecular disulfide bridges are C1-C98 and C29-C138. The glycan-linked threonine (Thr106) is underscored.
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the threonine of the consensus sequence for O-glycosyla-
tion of human IFND2b are highlighted (Fig. 1B). The cal-
culated molecular weight of the mature core protein (a.a.
24–188) of IFND2b is 19,269 Da. In order to generate
IFND2b-producing cells, HEK293 were transfected with
linearized pYD7-IFND2b and selected in the presence of
blasticidin. The D9 clone, which stably produces IFND2b
was isolated as described in material and methods. The
production of IFND2b with the D9 clone was performed
in fed-batch culture. Daily samples from the culture
media taken over a period of 9 days were analysed by
Coomassie blue-stained gel (Fig. 2A). The gel shows that
cell-derived contaminating proteins begin to accumulate
significantly after day 5. A decline in cell viability was also
notable after day 7 (Fig. 2B). Fed-batch cultivation was
terminated and the culture medium harvested. It is note-
worthy that early during production, HEK293-derived
IFND2b migrates with an apparent molecular weight of 2
kDa greater than its predicted mass calculated from the
amino acid sequence (19,3 kDa), while at around day 4, a
less abundant band of ~19,5 kDa appears. In order to
ascertain that this band is also IFND2b, N-terminal
sequencing was performed on both products. The
sequences obtained were identical and read NH2-C-D-L-P-
Q-T, as expected for N-terminal sequence of human
IFND2b having a correctly processed signal peptide, there-
fore suggesting that heterogeneous posttranslational
modifications may account for differences in electro-
phoretic mobilities of these two IFND2b species.
Purification of recombinant IFND2b by cation exchange 
chromatography and analysis by gel filtration and SDS-
PAGE
At the end of the production phase, the IFND2b is purified
as described in the Methods section. The IFND2b eluted in
a single peak at pH 4,5–4,6 from the cation exchange col-
umn (Fig. 3A). The electrophoretic profiles of proteins
contained in the harvest, the acid precipitate, the clarified
harvest and eluted fractions, are shown on a Coomassie
blue-stained gel (Fig. 3B). The acidification step was selec-
tive in removing protein contaminants, as the concentra-
tion of IFND2b in the clarified media was greater than
95% of that quantified in the harvest. The absence of
IFND2b in the flow through and in the wash suggests that
IFND2b strongly binds to the SO3- column. According to
a conservative estimate performed by densitometric anal-
ysis of the SDS-PAGE resolved purified material, the
purity of IFND2b exceeds 98% after the SO3- column and
the final desalting step.
Following desalting in PBS, purified IFND2b was loaded
on a Superdex 75 gel filtration column. The protein eluted
as a single peak with elution volume identical to that of
ovalbumin, a 44 kDa protein, indicating that purified
HEK293-IFND2b is not aggregated and suggesting that it
may form dimers at neutral pH (Fig. 4A). A Coomassie
blue-stained gel of IFN-containing fractions shows diffuse
wide bands as observed with non-purified material (Fig.
4B). These species with different electrophoretic mobili-
ties reflect glycosylation heterogeneity, which was later
confirmed by mass spectroscopy and glycosylation analy-
sis. Under reducing conditions, purified IFND2b migrates
as a major band of approximately 21 kDa and a less abun-
dant band of lower molecular weight. Mass spectroscopy
analysis indicates variations in the molecular weight
between 19,922 and 20,659 Da (Fig. 6B). Under non-
reducing conditions, IFND2b migrates with an apparent
molecular weight of ~17 kDa, a greater electrophoretic
mobility typical of the presence of intramolecular
disulfide bridges (Fig. 4C). The absence of dimers (i.e. ~42
kDa band) in non-reducing conditions indicates that the
probable formation of dimers as suggested by gel filtra-
tion analysis is independent of intermolecular disulfide
bridges. This non-covalent dimeric form of interferon has
already been described and involves coordination of a
zinc ion by two adjacent glutamic acid residues (E41 and
E42) from each of two IFN molecules [38].
The D9 clone produces hundreds of milligrams of IFND2b 
per liter of culture that are efficiently recovered
IFND2b in the crude harvests of fed-batch cultures was
quantified by ELISA. The average concentration from two
independent productions is 237 ± 11 mg/L, and this was
increased to 301 ± 25 mg/L when glucose and glutamine
feeds were added during production (Table 1). IFND2b
recovered from the SO3- column measured by ELISA cor-
related well with measures obtained with a Bradford assay
and by absorbance at 280 nm using IFND2b molar extinc-
tion coefficient. The concentrations of IFND2b measured
by ELISA in the harvest and in the recovered fraction from
the SO3- column were used to determine the recovery. The
mean concentration of IFND2b shows that between 70
and 80% of the IFND2b produced could be recovered, for
two independent productions for each condition (Table
1). These results were comparable in terms of volumetric
productivity and recovery to some productions of non-
glycosylated IFND2b performed in E. coli and in the meth-
ylotrophic yeast Pichia pastoris (Table 2).
IFND2b produced in HEK293 is O-glycosylated, highly 
sialylated and biologically active
One of the major interests for producing IFND2b in mam-
malian cells is to generate a glycosylated active protein.
The apparent molecular weight of IFND2b observed on
SDS-PAGE suggests that IFND2b produced in HEK293
undergoes post-translational modifications. There is also
a less abundant product of around 19,5 kDa on SDS-
PAGE.
BMC Biotechnology 2008, 8:65 http://www.biomedcentral.com/1472-6750/8/65
Page 5 of 16
(page number not for citation purposes)
Kinetics of cell growth and IFND2b production from D9 clone in fed-batch cultureF gure 2
Kinetics of cell growth and IFND2b production from D9 clone in fed-batch culture. D9 cells were seeded at a cell 
density of 0,25 × 106 cells per mL, fed with 0,1% TN1 the next day and sampled every day. A) Coomassie-stained SDS-PAGE 
analysis of the culture medium (20 PL) collected daily. B) Cell counts and viability were measured at the indicated times.
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Purification of IFND2b by cation-exchange chromatographyFigure 3
Purification of IFND2b by cation-exchange chromatography. A) A typical chromatographic profile of a purification of 
HEK293-produced IFND2b from a 400 mL fed-batch culture is illustrated. Solid line shows the 280 nM absorbance profile. 
Dotted line shows pH variations. IFND2b elutes in a single peak between 1000 and 1200 mL. B) Coomassie-stained SDS-PAGE 
analysis of 20 PL samples collected at different steps of production and purification of IFND2b. 1- crude harvest. 2- precipitate 
(equivalent to 200 PL of harvest volume). 3- clarified harvest. 4- flow through SO3- column. 5- wash SO3- column. 6- elution 
peak SO3- column. 7- desalted IFND2b in PBS.
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Purified IFND2b is not aggregated and forms dimers at neutral pH independent of intermolecular cystine formationFigure 4
Purified IFND2b is not aggregated and forms dimers at neutral pH independent of intermolecular cystine for-
mation. Following a desalting step in neutral PBS, purified IFND2b was analysed for dimer formation. A) Twenty mg of puri-
fied IFND2b were analysed on a Superdex 75 HR16/60 column equilibrated with PBS at pH 7,0. The arrows and numbers 
above indicate the elution volumes of molecular weight standards eluted in the same conditions. Purified IFND2b elutes in the 
same volume as ovalbumin, a 44 kDa globular protein. B) Coomassie-stained SDS-PAGE analysis of samples (20 PL) of each of 
the 10 fractions (4 mL) collected between elution volumes 40–80 mL. C) Coomassie-stained SDS-PAGE analysis of reduced 
and non-reduced IFND2b from HEK293 cells.
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We next determined whether IFND2b produced in
HEK293 is O-glycosylated [39] and sialylated as previ-
ously reported for IFND2b produced by human peripheral
blood leucocytes [40]. We performed a sequential diges-
tion of purified IFND2b with neuraminidase and O-gly-
cosidase to respectively remove sialic acid residues and O-
linked saccharides. Each digestion successively increases
the electrophoretic mobility of purified IFND2b to gener-
ate a deglycosylated product that migrates as fast as non-
glycosylated recombinant IFND2b produced E. coli (Fig.
5). This suggests that IFND2b produced in HEK293 cells is
O-glycosylated and sialylated. Note here the quasi
absence of the lower ~19,5 kDa product in the lane con-
taining the non-digested IFN. We found that the majority
of this product is lost during the purification process, as
most of it remains bound to the column (data not
shown). A minor band with lower electrophoretic mobil-
ity was still visible after glycosidases treatment, suggesting
that this species might be Core 2 type glycan.
A detailed mass analysis and glycosylation pattern of the
purified IFND2b was next performed by mass spectros-
copy. Electrospray ionization (ESI) mass spectrum exhib-
iting the glycoform profiles associated with each charge
state of purified IFND2b is shown (Fig. 6A). The masses of
the principal glycoform of this protein correspond to the
mature IFND2b peptide chain plus the glycans indicated
(Fig. 6B). The most intense peak at 20 213 Da appears to
be composed of the mature peptide chain plus a single
core type-1 disialylated glycan (Hex1HexNAc1SA2). A MS/
MS analysis of the tryptic glycopeptides confirms the com-
position of this glycan. The sialylated (mono and disia-
lylated) glycoforms appear to constitute 75% of the total
species. This percentage is likely to be underestimated, as
some of the other peaks that cannot be assigned easily
may be sialylated as well. The disialylated type 1 glyco-
form represents 50% of the total peak area while the mon-
osialylated glycoform is 10% of the total. Using electron
transfer dissociation, we also show that the glycan is
linked to the expected threonine residue at position 106
(Fig. 7).
Finally, we tested the purified glycosylated IFND2b pro-
duced in HEK293 for in vitro biological activity in compar-
ison to non-glycosylated form produced in E. coli. Using a
reporter gene assay we show that HEK-produced IFND2b
is biologically active as it induces the production of a
secreted alkaline phosphatase (SEAP) reporter enzyme
under the control of the human ISG56 promoter (Fig. 8).
This assay shows that HEK-produced IFND2b is as active
Table 1: Quantification and recovery of HEK293-produced IFND2b from two production schemes.
Production scheme IFND2b mg/L (ELISA) Percent recovery
Culture medium SO3-column
1 feed 237 ± 11 185 ± 3 79.5
2 feeds 301 ± 25 216 ± 11 71.8
Table 2: Overview of human recombinant IFND2b production in prokaryotic and eukaryotic systems.
Host mg/L Recovery Purity % Glycosylation Activity IU/mg* Ref.
mg/L %
Prokaryotic
E. coli 5200 3000 58 ND No 3 × 109 [21]
E. coli 4000 300 7,5 ND No 2,5 × 108 [19]
E. coli 3500 600 12 100 No ND [20]
S. lividans 0,01 ND ND ND No 0,4 × 104 [55]
Eukaryotic
Pichia pastoris 450 298 66,2 > 95 ND 1,9 × 109 [56]
Pichia pastoris 200 ND ND ND No 3.0 × 108 [57]
Tobacco BY2 cells 0.02 ND ND ND No ND [58]
Insect Sf9 cells ND ND ND ND Partial (no sialylation) 2,3 × 108 [34]
Mouse NS0 cells 120 ND ND ND Yes 2 × 108 [36]
* IFND2b activity has been determined by inhibition of viral replication. Different viruses and hosts were used.
BMC Biotechnology 2008, 8:65 http://www.biomedcentral.com/1472-6750/8/65
Page 9 of 16
(page number not for citation purposes)
in vitro as bacterially produced IFND2b. In addition, viral
challenges using Vesicular stomatitis virus (VSV) on
Madin-Darby Bovine Kidney (MDBK) cells or using
Encephalomyocarditis virus (EMCV) on human A549
cells demonstrated very good antiviral activity of purified
IFND2b with titres ranging from 4.1 to 12.2 × 108 IU/mg
for two independent batches (Table 3).
Discussion
We describe here the generation of a HEK293 cell clone
(D9) able to stably produce glycosylated human recom-
binant IFND2b for culture periods up to 4 months in the
absence of selection. The volumetric production per litre
of serum-free culture can reach more than 300 mg/L, and
is the highest volumetric production of IFND2b reported
for a mammalian system. We have further developed a
rapid and reliable method for its efficient recovery and
show that HEK-derived IFND2b is O-glycosylated, sia-
lylated and biologically active.
Gel filtration analysis of purified IFND2b suggests that it
may exist as a dimer in PBS at neutral pH. A zinc-depend-
ent dimeric form of hIFND2b as already been observed
[38] and was also reported for the structurally homolo-
gous human IFNE [41]. It is believed that interferon is bio-
logically active as a monomer and the biological
significance of zinc-mediated dimerization is currently
unknown. The fact that our IFN is biologically active sug-
gests that at the low concentration used in the bioactivity
assays, it may exist in solution as a monomer.
To date, the production of recombinant IFND2b and other
cytokines in mammalian systems, particularly the devel-
opment of clones stably expressing a cytokine of interest,
has not been well exploited due to limitations in the vol-
umetric productivity. One of the possible causes maybe
that many cytokines exhibit strong anti-proliferative and
cytotoxic activities on diverse cell lines [42,43], therefore
strongly selecting against clones that show high cytokine
expression levels. The D9 clone nonetheless grew almost
as well as parental cells indicating that HEK293 cells can
adapt to proliferate in the presence of high levels of
IFND2b. This adaptability of HEK293 cells to a growth
inhibitory cytokine suggests that they may be suitable for
the large-scale production of other interferons and
cytokines.
To our knowledge, no comparable expression system
exists in order to contrast the volumetric productivity of
our HEK293 clone. However, this clone performs very
well compared to other reported eukaryotic expression
systems (see table 2 for an overview of IFND2b expression
systems). Nevertheless, a much greater volumetric pro-
duction can be obtained from E. coli expression systems.
Although we believe that the production capacity of
HEK293 cells for IFND2b can be improved, we doubt that
such productivity can ever be achieved in mammalian
cells, at least for a cytokine. It is obvious however that the
difficulty in obtaining high recovery of refolded IFND2b is
still an important challenge with E. coli. In general, purifi-
cations of recombinant proteins from prokaryotes usually
require extraction from inclusion bodies and complex
refolding procedures, which reduce recovery yields [44].
Protein refolding is a critical step in the processing of bio-
therapeutics, as incompletely refolded species lower spe-
cific activity and may trigger an immune response.
Antibodies to recombinant prokaryotic IFND2b have been
detected in HCV patients with acquired resistance to
HEK293-produced human IFND2b is sialylated and O-glyco-sylatedFigure 5
HEK293-produced human IFND2b is sialylated and 
O-glycosylated. IFND2b was deglycosylated as described in 
material and methods. 1- 10 Pg of purified HEK-produced 
IFND2b. 2- 10 Pg of purified HEK-produced IFND2b digested 
with neuraminidase. 3- 10 Pg of purified HEK-produced 
IFND2b digested with O-glycosidase. 4- 10 Pg of purified E. 
coli-produced IFND2b.
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ESI-MS analysis of the intact IFND2b glycoproteinFigure 6
ESI-MS analysis of the intact IFND2b glycoprotein. A) ESI mass spectrum exhibiting the glycoform profiles associated 
with each charge state of the protein and B) the glycoprotein molecule weight profile reconstructed from the mass spectrum 
in panel A. The most intense peak at 20,213 Da appears to be composed of the mature peptide chain plus a single core type-1 
disialylated glycan (Hex1HexNAc1SA2).
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Figure 7
CID and ETD analysis of the tryptic glycopeptides from IFND2b. A) CID-MS/MS spectrum of the triply protonated 
ion at m/z 1426.8 corresponding to the disialylated glycopeptide of T84-112. The spectrum is dominated by the sequential neu-
tral loss of the glycan components from the doubly protonated glycopeptide ion. The principal b and y fragment ions arising 
from fragmentation of the peptide backbone are indicated in the spectrum as are the compositions the glycan oxonium ions 
observed m/z 494.9, 657.0 and 948.0, respectively. The sequence of the peptide is provided in the inset. B) CID-MS/MS spec-
trum of the triply protonated ion at m/z 1340.8 corresponding to the monosialylated glycopeptide of T84-112. Note that the 
neutral loss corresponding to a second sialic acid is missing from this spectrum as is the corresponding oxonium ion at m/z 
948.0. C) ETD MS/MS spectrum of the triply protonated, monosialylated T84-112 glycopeptide at m/z 1340.8. The higher m/z 
region of the ETD spectrum contained the most informative fragment ions and is presented here. The c ion series indicated in 
the spectrum clearly identified the site of O-linkage as Threonine 106 of the mature protein.
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IFND2b treatment [26,27], although it is not clear
whether denatured IFND2b played a role in this case.
Because the vast majority of biotherapeutics including
growth factors, cytokines and antibodies are secreted pro-
teins, mammalian systems, unlike prokaryotes, allow for
production in perfusion as well as for the development of
non-denaturing purification procedures. The first and
foremost advantage of producing human recombinant
proteins in mammalian systems is to generate proteins
with the necessary posttranslational modifications
required for full biological activity. N-glycosylation in
particular, is often required for proper protein folding
[45], protein-protein interactions, stability and optimal
pharmacokinetics [46]. Although O-glycosylation is less
critical for structure and function of proteins, it has been
shown for example to increase the serum half-life of
IGFBP6 by 2,3 folds over the non-glycosylated protein
[47] and to protect against proteolysis [48]. In a recent
randomized study, O-glycosylated IFND2b was shown to
have an increased serum half life in comparison to non-
glycosylated IFND2b [32]. We show here that human
recombinant IFND2b produced in HEK293 cells is O-gly-
cosylated and extensively sialylated. Despite heterogene-
ity in the glycan structures, the nature and distribution of
glycan moieties are quite similar to IFND2b naturally pro-
duced by human leukocytes [40]. Approximately 50% of
the purified protein is disialylated, while another 10% is
monosialylated, in comparison to 50% and 30% respec-
tively for leukocyte-derived IFN. As expected from its bio-
chemical structure, we show that HEK293-produced
IFND2b has a biological activity comparable to that of
non-glycosylated E. coli-produced IFND2b by means of an
in vitro reporter-gene assay, indicating that IFND2b is not
inactivated by the purification process. This was also con-
firmed by the high specific activity ranging from 4.1 to
12.2 × 108 IU/mg using two different batches of purified
IFN and two antiviral assays.
Conclusion
While additional studies are needed to determine whether
HEK293-produced IFND2b can offer advantages over
non-glycosylated or pegylated IFN for in vivo applications,
this work demonstrates that the HEK293 cell line is a suit-
able host for the high volumetric production of glyco-
sylated human recombinant IFND2b and potentially
other cytokines.
Methods
Material
The expression plasmid was purified with a maxi-prep
plasmid purification kit (Qiagen, Mississauga, ON, Can-
ada). F17 serum-free culture media and blasticidin were
obtained from Invitrogen (Carlsbad, CA). Pluronic F68
and glutamine were from Sigma-Aldrich (St. Louis, MO)
and Tryptone N1 from Organotechnie (La Courneuve,
France). Reagents for IFND2b purification and electro-
phoresis include anhydrous citric acid and tri-Na citrate
Table 3: Assessment of biological activity of HEK293-produced IFND2b using two antiviral assays
Antiviral assay IFND2b activity (U/mg)
HEK293 (1 feed) E. coli HEK293 (2 feeds) E. coli
MDBK/VSV 4.1 × 108 3.1 × 108 12.2 × 108 4.0 × 108
A549/EMCV 6.0 × 108 3.9 × 108 7.2 × 108 8.1 × 108
IFND2b activity has been determined by inhibition of viral replication of vesicular stomatitis virus (VSV) in Madin Darby bovine kidney cells (MDBK) 
and of encephalomyocarditis virus (ECMV) in the lung carcinoma cell line A-549. Both antiviral assays were carried out by PBL InterferonSource. In 
each assay performed independently, E. coli IFND2b was used as a positive control.
HEK293-produced human IFND2b is biologically activeFigure 8
HEK293-produced human IFND2b is biologically 
active. The biological activity of HEK293-produced human 
IFND2b was assayed with a gene reporter assay and com-
pared to E. coli-produced human recombinant IFND2b as 
described in material and methods. The activity of the 
secreted alkaline phosphatase is plotted against the concen-
tration of IFND2b produced in the two hosts. Each point 
represents the average ± SEM of 3 experiments performed in 
triplicate.
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(EMD Chemicals Inc, Darmstadt, Germany), 0.45 Pm fil-
tering units (Millipore, Bedford, MA), NaCl (Sigma-
Aldrich, St. Louis, MO), Fractogel* SO3- (M) (Merck
KGaA, Darmstadt, Germany), Econo-Pac® 10 columns
(Bio-Rad Laboratories), Bradford Reagent (Biorad, Her-
cules, CA), 2 Pm filters (Pall Corp, Ann Arbor, MI),
NuPAGE Bis Tris 4–12% gradient gels, MES 20× buffer
(Invitrogen, Carlsbad, CA), and Coomassie R250 stain
(Sigma-Aldrich, St. Louis, MO). Trypsin (Promega, Madi-
son WI), neuraminidase, dithiothreitol, iodoacetamide
and guanidine HCl (Sigma-Aldrich, St. Louis, MO), O-gly-
cosidase (Roche), Tris HCl, (Bio-Rad, Mississauga, ON),
high purity acetonitrile, formic acid and ammonium
bicarbonate (VWR International, Montreal, QC) and Cen-
tricon 3,000 MWL centrifugal filters (Millipore, Bedford,
MA) were used for glycosylation analysis. The IFND anti-
body and ELISA kit are from PBL InterferonSource (Piscat-
away, NJ, USA) and bacterially produced IFND2b from
Cell Sciences Inc (Norwood, MA, USA). pNifty2-56K-
SEAP plasmid is from Invivogen (San Diego, USA).
IFND2b expression plasmid
The IFND2b gene was synthesized with human-optimized
codons (Geneart AG, Regensburg, Germany) according to
the Genebank sequence no. AY255838. The synthetic
cDNA was inserted as a BamHI/EcoRI fragment down-
stream of the cytomegalovirus (CMV) promoter into the
pYD7 expression plasmid. This plasmid is a derivative of
the previously described pTT vector [37] encoding the
original functional elements in addition to a blasticidin
resistance cassette.
Engineering of a HEK293 clone stably expressing IFND2b 
and fed-batch production
A HEK293 cell line constitutively expressing the EBNA1
protein of EBV (clone 6E) was used to generate IFN-pro-
ducing clones. HEK293-6E and IFN-producing clone are
grown in suspension in serum-free F17 culture media sup-
plemented with 0.1% pluronic F68. Cultures were grown
at 37°C and 5% CO2 under constant agitation (120 rpm).
HEK293-6E were transfected as previously described [37]
with PvuI-linearized pYD7/IFND2b and selected in the
presence of 2 Pg/mL of blasticidin. The blasticidin resist-
ant cells were next seeded into 96 well plates at 1 cell/well
without blasticidin. After 3–4 weeks, emerging clones
were expanded (in the absence of blasticidin) and tested
for IFND2b expression by dot blot. The selection of IFN-
producing clones was based on the levels of IFND2b
expression and growth properties of the clones. The high-
est producers were amplified as suspension cultures and
tested for IFND2b accumulation over a 4 days culture.
One clone, identified as D9, was selected because it is sta-
bly producing high IFND2b levels while maintaining a
high growth rate (doubling time of 26 hours-1). For
IFND2b production, cells were seeded at a density of 0,25
× 106 cells/mL in F17 antibiotic-free media in shaker
flasks. Twenty-four hours post-seeding, the cultures were
fed with 0,5% peptones [37,49] and left in the incubator
for an additional 7–8 days. Optional addition of 20 mM
glucose and 5 mM glutamine was performed 4 days post
seeding where indicated.
Purification of IFND2b
The culture medium of a fed-batch culture was collected
by centrifugation at 1000 g for 10 min. The supernatant
was then acidified to pH 3.6–3.8 with 1 M citric acid.
Acidification caused the formation of a precipitate which
was removed by centrifugation. The clarified supernatant
was then filtered on a 0.45 Pm filtering unit. Purification
of IFND2b from the filtered supernatant was performed
on an ÄKTA Explorer system (GE healthcare, Baie D'Urfé,
QC, Canada). The supernatant was loaded at a flow rate of
10 mL/min on a Fractogel SO3-cation exchange column,
previously equilibrated with 0,1 M Tri-Na citrate buffer
pH 3,5 containing 0,35 M NaCl. Following a wash with 2
column volumes of the equilibration buffer, the IFND2b
was then eluted with a pH gradient. The pH of the mobile
phase was increased from pH 3,5 to pH 6,0 with 0,1 M Tri-
Na citrate buffer pH 6.0, plus 0,35 M NaCl. The fractions
containing IFND2b were pooled. An additional desalting
step was performed on Econo-Pac® 10 columns according
to the manufacturer's specifications. For the determina-
tion of glycosylation by enzymatic digestion, the purified
IFND2b was desalted in 0.1 M NH4HCO3 buffer pH 5 and
lyophilized, whereas for bioassays, the purified IFND2b
was desalted in PBS and sterile filtered.
Quantification and purity of IFND2b
IFND2b recovered from the SO3- column was quantified
by measuring absorption at 280 in a spectrophotometer,
with a Nanodrop ND-1000 (Fisher Scientific, Montreal,
QC, Canada), with a Bradford assay and by ELISA accord-
ing to the manufacturer's protocol. The concentration in
the harvest was measured with ELISA and used to calcu-
late the percent recovery. To assess the purity level of
IFND2b, 3 Pg were analyzed by SDS-PAGE followed by
Coomassie staining.
N-terminal sequencing and enzymatic determination of 
glycosylation of purified IFND2b
As HEK293-produced IFND2b migrates as two bands on
SDS-PAGE, N-terminal amino acid sequences from both
bands were obtained by automated sequencing per-
formed at our sequencing facility. Enzymatic treatments
with neuraminidase and O-glycosidase were performed to
remove sialic acid and O-linked sugars respectively.
Sequential digestions were performed in 50 mM phos-
phate buffer pH 5,0 on 100 Pg of purified/desalted
IFND2b. Removal of sialic acid was done with 0.5 IU of
neuraminidase for 1 h at 37°C followed by addition of 15
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mU of O-glycosidase. Non-glycosylated recombinant
IFND2b from E. coli and glycosylated and deglycosylated
HEK293-produced IFND2b were resolved on SDS-PAGE
in parallel to compare migration profiles. Migration pro-
files of glycosylated and deglycosylated HEK293-pro-
duced IFND2b were compared to non-glycosylated
IFND2b produced in E. coli.
Analysis of intact IFND2b by mass spectrometry
The protein solution (~1 Pg/PL in PBS buffer) was
desalted by filtration on a 3 000 MWL Centricon filter and
diluted to its original concentration with deionized water.
The solution was adjusted to 20% acetonitrile, 0.2% for-
mic acid just prior to infusion at 1 PL/min into the elec-
trospray interface of a Q-TOF 2 hybrid quadrupole time-
of-flight mass spectrometer (Waters, Milford, MA). The
mass spectrometer was set to acquire one spectrum every
2 seconds over the mass range, m/z 800–2600. The pro-
tein molecular weight profile was generated from the
mass spectrum using MaxEnt (Waters).
Sequence analysis of the tryptic glycopeptides from 
purified IFND2b
Purified IFND2b was reduced, alkylated and digested with
trypsin according to standard protocols. In summary,
approximately 100 Pg of the protein was dissolved in 1M
Tris HCl, 6M guanidine HCl, pH 7.5 containing 2 mM
dithiothreitol (DTT) and incubated at 50°C for 1 hour.
The reduced cysteines were converted to carboxyamid-
omethyl derivatives using 10-fold excess of iodoaceta-
mide over DTT. The protein solution was then
concentrated on a 3 000 MWL Centricon and diluted to
100 PL using 50 mM ammonium bicarbonate. This proc-
ess was repeated a second time. Trypsin (5 ug) was added
to the sample, which was then incubated overnight at
37°C.
The tryptic digest was analyzed and fractionated by LC-MS
using an Agilent 1100 HPLC system coupled with the Q-
TOF2 mass spectrometer. Approximately 60 Pg of the pro-
tein digest was injected onto a 4.6 mm × 250 cm Jupiter,
5 Pm, 300 Å, C18 column (Phenomenex, Torrance, CA)
and resolved using the following gradient conditions: 5%
to 60% acetonitrile, 0.2% formic acid in 45 minutes,
increasing to 95% after 50 minutes (1 mL/min flow rate).
Approximately, 60 PL/min of the HPLC eluate was
directed to the mass spectrometer while the remainder
was collected in 1 minute fractions. The Q-TOF2 mass
spectrometer was set to acquire 1 spectrum per second
(m/z 150–2000) whilst cycling between a low and high
offset voltage within the collision cell (10 V and 35V,
respectively). This enabled the simultaneous detection of
intact peptide and glycopeptide ions in the higher m/z
regions (low offset mode) as well as the unique glycan
oxonium ions in the lower regions of the spectrum (high
offset mode). By screening the fractions in this manner it
was possible to determine that only two of them (frac-
tions 25–26 and 26–27 minutes, respectively) contained
glycopeptides.
Glycopeptides were interrogated by collision induced dis-
sociation (CID) to determine their amino acid sequence
and glycan composition and by electron transfer dissocia-
tion (ETD) to identify the site of linkage. ETD preserves
delicate modifications intact during the fragmentation
process and is ideal for identifying the linkage sites of O-
glycans [50-52]. The glycopeptide-containing fractions
were infused at 1 PL/min into the electrospray ionization
source of a LTQ XL linear ion trap (Thermo Fisher Scien-
tific) capable of performing ETD. The CID collision volt-
age was adjusted for optimum production of peptide
fragment ions from the multiply charge glycopeptide pre-
cursor ions (typically 25–30 V). ETD was performed using
fluoranthene as the anionic reagent and with supplemen-
tary activation enabled. The optimal ETD reaction time for
these glycopeptides was 350 msec.
Biological activity
A SEAP reporter gene assay based on expression plasmid
containing an IFN-inducible promoter (pNiFty2) was
used to assess the biological activity of glycosylated
HEK293-produced IFND2b in comparison to non-glyco-
sylated IFND2b. HEK293 cells were transfected with the
pNiFty2 reporter plasmid, which encodes the secreted
embryonic alkaline phosphatase (SEAP) under the con-
trol of the human ISG56 promoter. Transfected cells were
plated in 96 well plates at a cell density of 105 cells/mL
and stimulated, 24 h post-transfection, with IFND2b at
the indicated concentrations. Following an additional 48
h period of incubation, the supernatants were collected
and assayed for SEAP activity. The hydrolysis of paranitro-
phenyl phosphate (pNPP) was measured as a function of
time to determine SEAP activity induced with IFN treat-
ments, as previously described [53]. The SEAP activity is
expressed as the increase in absorbance units at 410 nm
per minute.
Antiviral assays were carried out by PBL InterferonSource
(Piscataway, NJ) using Madin-Darby Bovine Kidney
(MDBK) cells challenged by Vesicular stomatitis virus or
human A549 cells challenged with encephalomyocarditis
virus [54]. Cells were incubated with two-fold serial dilu-
tions of IFND2b standard (PBL InterferonSource), 293-
IFND2b, or control (Media). After 24 h incubation with
the virus, cell viability was determined via crystal violet
staining (570 nm absorbance). The sample titer (IC50),
calculated by SigmaPlot software (SPSS Inc., Point Rich-
mond, CA), was based on the 50% cytopathic effect of the
assay. Units of anti-viral activity were based on the titer of
a PBL lab standard, which was determined against the
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NIH reference standard for human IFND2b (Gxa01-901-
535).
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